Please ensure Javascript is enabled for purposes of website accessibility

Merck's Insomnia Drug Approved for Alzheimer's Patients

By Jim Crumly – Feb 3, 2020 at 2:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Trouble sleeping is common among sufferers of Alzheimer's disease.

Merck (MRK -1.26%) received approval from the U.S. Food and Drug Administration to market its insomnia drug Belsomra (suvorexant) for treating sleep disruption in patients with mild-to-moderate Alzheimer's disease. Belsomra was approved by the FDA for the general population in 2014, but Monday's decision allows Merck to include information on the drug's effectiveness in Alzheimer's patients in its prescribing information.

Last May, Merck reported the results of a phase 3 clinical trial of Belsomra in 285 Alzheimer's patients, announcing that the study had met its primary efficacy endpoint. After four weeks of treatment, total sleep time in the Belsoma group increased 73.4 minutes compared with 45.2 minutes in the placebo group. The most common adverse effect was drowsiness the next day.

Young woman at the bedside of an Alzheimer's patient.

Image source: Getty Images.

Disruption of sleep-wake patterns and difficulty sleeping is common among Alzheimer's patients, affecting about 40% of the population, and there's emerging evidence that poor sleep may contribute to the development of the disease and impairment of memory function.

Physicians use caution in prescribing the most popular sleep drugs such as Sanofi's Ambien to Alzheimer's patients because they may contribute to confusion and falls. Belsomra is the first drug to use a different mechanism that operates on the specific part of the brain that helps keep a person awake.

Sales of Belsomra by the pharmaceutical giant in 2018 were $260 million, up 24% from the year before.

Jim Crumly owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$85.69 (-1.26%) $-1.09
Sanofi Stock Quote
Sanofi
SNY
$37.49 (-2.38%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.